)
)
)
Oncolytics (Nasdaq:ONCY)
March 03, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Oncology
Oncolytics is developing pelareorep, the only dsRNA REO virus being developed as an immunotherapy treatment for various tumors, including KRAS mutant MSS mCRC and 2L anal cancer. Pelareorep has achieved 2-3x the efficacy benchmarks versus standard of care treatment in colorectal, anal and pancreatic cancer. The company is led by former head of legal and strategy at Ambrx, Jared Kelly.
Year Founded:
1999
Lead Product in Development:
Pelareorep
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
